Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.1 0.08

Overview

Share price change

24h

Current

Min

11.68

Max

12.13

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

125.5

57.002

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.49% upside

Market Stats

By TradingEconomics

Market Cap

269M

2.2B

Previous open

12.02

Previous close

12.1

News Sentiment

By Acuity

100%

0%

329 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 23:52 UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

14 sie 2026, 23:51 UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

14 sie 2026, 23:51 UTC

News

Tyson Foods will close its beef facility in Joslin, Illinois, resulting in about 2,500 job losses, as shares trade lower in after-market hours.

14 sie 2026, 23:46 UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from a securities fraud lawsuit related to its RP1 application.

14 sie 2026, 23:46 UTC

News

Delek US Holdings shares rose in after-market hours following Delek Logistics Partners' $230 million public offering of common units at $50.00 each.

14 sie 2026, 23:46 UTC

News

Patterson-UTI Energy reported 98 drilling rigs operating in July. Shares rose in after-market trading, reflecting strong activity and nearing the upper end of their one-month range.

14 sie 2026, 23:46 UTC

News

Kraft Heinz Co shares are lower in after-market trading following a $100 million marketing announcement and concerns over July's U.S. retail sales drop.

14 sie 2026, 23:41 UTC

News

Elliott Investment Management increased its stake in Hewlett Packard Enterprise by 17.7%, contributing to higher after-market trading for the shares.

14 sie 2026, 23:36 UTC

News

Dynatrace shares are higher in after-hours trading following Starboard Value's SEC filing disclosing an 8.9 million share stake.

14 sie 2026, 23:31 UTC

News

Texas Pacific Land Corp shares are higher in after-market hours, with a current price of $358.89 and a market capitalization of $24.75 billion.

14 sie 2026, 23:31 UTC

News

Jana Partners disclosed a new stake in Rapid7 Inc, acquiring over 6.7 million shares. Shares advanced during after-market hours following the announcement.

14 sie 2026, 23:21 UTC

News

MongoDB Inc. showcases AI focus with new Atlas Managed MCP Server tools and Voyage AI features. Shares are little changed in after-market trading.

14 sie 2026, 23:21 UTC

News

Constellation Brands shares are trading lower after Berkshire Hathaway dissolved its stake, contributing to negative sentiment amid broader weakness in the Distillers & Vintners sector.

14 sie 2026, 23:21 UTC

News

Embecta Corp shares are lower in after-market hours amid negative sentiment from two class action lawsuits alleging securities fraud and disappointing second-quarter guidance.

14 sie 2026, 23:11 UTC

News

Lattice Semiconductor granted over 414,000 RSUs and PRSUs to new employees as part of its equity incentive plan. Shares are trading roughly flat in after-market hours.

14 sie 2026, 23:11 UTC

News

Lone Pine Capital LLC reduced its stake in McKesson Corp by 85.3% to 57,851 shares, contributing to the stock's decline in after-market trading.

14 sie 2026, 23:06 UTC

News

Berkshire Hathaway raised its stake in Delta Air Lines by 44%, now holding 57.3 million shares. Shares are trading higher in after-market hours.

14 sie 2026, 23:06 UTC

News

Mastercard proposes a plan for Brazilian payment processors to absorb R$2.5 billion in losses from Banco Master’s collapse, as shares decline in after-market trading.

14 sie 2026, 23:06 UTC

News

Viking Global Investors has cut its stake in Walt Disney by a significant amount, while ValueAct Holdings has fully exited its position. Shares are lower in after-market trading.

14 sie 2026, 23:02 UTC

News

Target shares lower in after-market trading despite Telsey Advisory Group's Outperform rating and raised price target to $170. Broader market weakness weighs on performance.

14 sie 2026, 23:01 UTC

News

ServiceNow Inc shares fell in after-market trading to about $124.03 amid broader market concerns following a drop in U.S. retail sales.

14 sie 2026, 23:01 UTC

News

Berkshire Hathaway's Form 13F filing revealed a new position in DR Horton, boosting investor interest and driving shares higher in after-hours trading.

14 sie 2026, 23:01 UTC

News

Warner Bros Discovery Inc. shares declined in after-market hours amid regulatory scrutiny over its merger with Paramount Skydance Corp, facing opposition from state attorneys general.

14 sie 2026, 23:01 UTC

News
Social Media

Genco Shipping & Trading shares lower in after-market trading following Diana Shipping's withdrawal of its acquisition offer, citing unrealistic demands from Genco's Board.

14 sie 2026, 23:01 UTC

News
Social Media

Berkshire Hathaway increased its stake in Macy's to 7.3 million shares, contributing to positive sentiment as shares advanced in after-market trading.

14 sie 2026, 23:01 UTC

News

Baker Hughes Co shares are lower in after-market hours amid rising oil and gas rig counts and concerns over a decline in U.S. retail sales.

14 sie 2026, 23:01 UTC

News

MSCI Inc. shares are higher in after-market trading, reflecting a cumulative gain since Friday's close and a market capitalization of $41.38 billion.

14 sie 2026, 23:01 UTC

News

Berkshire Hathaway increased its stake in New York Times Co. by 3.7%, contributing to a modest rise in after-market trading.

14 sie 2026, 23:01 UTC

News

NIO shares rose during after-market hours to about $4.50, as options sentiment showed mixed signals ahead of the upcoming earnings report.

14 sie 2026, 23:01 UTC

News

Realty Income Corp closed a $1.0 billion private offering of convertible senior notes, with proceeds for share repurchases and debt repayment. Shares are higher in after-market trading.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

19.49% upside

12 Months Forecast

Average 14.53 USD  19.49%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat